OSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump

MT Newswires Live03-26

OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab "could offer meaningful clinical benefit" in patients with recurrent glioblastoma, a type of aggressive brain cancer.

The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.

The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.

The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.

OSR shares climbed by nearly 130% in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2522872068?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-03-26 20:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2522872068","market":"fut","top_or_hot":-1,"title":"OSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump","media":"MT Newswires Live","content":"<html><body><p> OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab \"could offer meaningful clinical benefit\" in patients with recurrent glioblastoma, a type of aggressive brain cancer.</p><p>The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.</p><p>The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.</p><p>The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.</p><p>OSR shares climbed by nearly 130% in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOSR Unit Vaximm Reports Positive Results for Brain Cancer Therapy; Shares Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-26 20:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab \"could offer meaningful clinical benefit\" in patients with recurrent glioblastoma, a type of aggressive brain cancer.</p><p>The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.</p><p>The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.</p><p>The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.</p><p>OSR shares climbed by nearly 130% in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2522872068","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2522872068","pubTimestamp":1742991188,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"OSR  subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab \"could offer meaningful clinical benefit\" in patients with recurrent glioblastoma, a type of aggressive brain cancer.The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.OSR shares climbed by nearly 130% in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSRH":"OSR Holdings"},"translate_title":"OSR单位Vaximm报告脑癌治疗的积极结果；股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSRH":0.9},"content_text":"OSR (OSRH) subsidiary Vaximm said Wednesday that final data from a phase 2a trial showed that its investigational vaccine VXM01 in combination with avelumab \"could offer meaningful clinical benefit\" in patients with recurrent glioblastoma, a type of aggressive brain cancer.The 25-patient trial also showed that the VXM01-avelumab combination therapy was well-tolerated and in line with previously reported data on avelumab alone, the company said.The non-resected patient cohort showed a 12.0% objective response rate, while 12.0% of these patients showed a partial remission and 4.0% had stable disease, the company said.The oral immunotherapy is designed to activate T-cells to attack tumor vasculature and cancer cells directly, the company said.OSR shares climbed by nearly 130% in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2522872068","isCrawlerRequest":true}